Health Catalyst, GitLab, Elastic, and Marqeta Shares Plummet, What You Need To Know
Shares of Health Catalyst, GitLab, Elastic, and Marqeta experienced significant drops after a Bloomberg report indicated Anthropic's Q2 revenue exceeded $11.5 billion, suggesting AI tools are gaining traction and potentially impacting software companies. This market reaction intensified existing pressure on software stocks, raising concerns about customers shifting budgets to AI assistants. Health Catalyst, in particular, saw a 7% decline, adding to its previous drop due to a weak Q3 revenue forecast and lowered full-year guidance.
Health Catalyst (HCAT) group led by Clint Coghill reports 9.6% ownership stake
A group of investment entities associated with Clint D. Coghill has reported a 9.6% ownership stake in Health Catalyst (HCAT) as of June 30, 2026. This includes direct holdings by Stoney Lonesome HF LP and Drake Helix Holdings, LLC. Clint D. Coghill and CDC Financial, Inc. are deemed to beneficially own a total of 7,095,498 shares, representing this 9.6% of outstanding shares.
HCAT Maintains by Wells Fargo -- Price Target Lowered to $1.50
Wells Fargo has maintained an Equal-Weight rating for Health Catalyst (HCAT) but lowered its price target to $1.50 from $1.75, citing concerns over growth expectations in a challenging healthcare environment. Despite this, GuruFocus assesses HCAT as 57.3% undervalued with a GF Value™ of $4.16 against a current price of $1.77, though its GF Score™ of 52/100 points to challenges in profitability and financial strength. Investors are advised to proceed with caution due to ongoing losses and cash flow issues, despite the perceived undervaluation.
Wells Fargo & Company Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price
Wells Fargo & Company has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $1.75 to $1.50, while maintaining an "equal weight" rating, suggesting a potential 15.49% downside. Despite recent quarterly earnings beating expectations with $0.04 EPS and $70.49 million in revenue, analyst sentiment remains cautious, resulting in an overall "Hold" consensus for the stock. The company continues to face a negative net margin and institutional investors hold a significant portion of its stock.
5 Must-Read Analyst Questions From Health Catalyst’s Q2 Earnings Call
Health Catalyst (HCAT) reported a notable decline in Q2 sales, attributed to client migrations and divestiture of its Vitalware business. While revenue slightly beat analyst estimates, the company lowered its full-year guidance and faces ongoing structural challenges in health systems. Analysts pressed management on future divestitures and the drivers behind the guidance reduction.
Health Catalyst sells VitalWare for $147Mn
Health Catalyst sold its VitalWare subsidiary to Med-Metrix for $147 million in cash, completed on July 31, 2026. This divestiture allowed Health Catalyst to eliminate its credit facility and focus entirely on healthcare intelligence, analytics, and AI. VitalWare, which provides mid-revenue cycle management solutions, generated $37 million in revenue in fiscal year 2025 and enhances Med-Metrix's software offerings.
Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from Analysts
Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $2.95. The company recently reported better-than-expected quarterly EPS of $0.04 and revenue of $70.49 million, though it remains unprofitable with a negative net margin. Institutional investors hold approximately 85% of the stock.
HCAT Maintained by Citigroup -- Price Target Lowered to $2.00
Citigroup has maintained a neutral rating for Health Catalyst (HCAT) but lowered its price target from $2.50 to $2.00. Despite the stock being potentially undervalued by 58.8% according to GuruFocus's GF Value, concerns remain about the company's profitability and valuation. Investors are advised to exercise caution due to ongoing financial struggles, even though gurus show cautious optimism.
Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup
Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.50 to $2.00, while maintaining a "neutral" rating, indicating a potential 12% upside from its previous close. Despite beating quarterly EPS and revenue estimates, the company continues to report substantial losses, and analysts forecast a full-year loss. The consensus among analysts is a "Hold" rating with an average price target of $2.95, reflecting mixed but cautious sentiment.
Health Catalyst (NASDAQ:HCAT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Health Catalyst (NASDAQ:HCAT) reported stronger-than-expected Q2 earnings, with an adjusted EPS of $0.04 and revenue of $70.49 million, surpassing analyst estimates. Despite the beat, the company cut its Q3 and full-year 2026 revenue guidance due to anticipated migration-related churn and costs, leading to a significant 25% drop in stock price. Health Catalyst also completed the divestiture of Vitalware and Med-Metrix for $147 million, using the proceeds to become debt-free.
Health Catalyst (HCAT) Stock Price Sinks On Margin Reset Fears
Health Catalyst (HCAT) saw its stock price drop by 25% following its Q2 2026 report, despite headline numbers not indicating a collapse. The decline is attributed to investor concerns over a changing margin profile due to the sale of the Vitalware unit, the transition to the Ignite platform, and new guidance. The company's Q2 revenue was US$70.5 million, with an adjusted EBITDA of US$9.9 million, but expectations for full-year adjusted gross margin below 50% and a sharp revenue step-down in Q3 have fueled bearish sentiment.
Health Catalyst, Inc. Q2 2026 Earnings Call Summary
Health Catalyst, Inc. recently held its Q2 2026 earnings call, detailing a strategic pivot following the divestiture of its Vitalware business for $147 million. This move allowed the company to repay $160 million in debt and focus on core technology, particularly its 'Project Nexus' strategy. Management anticipates continued revenue headwinds from platform migrations but remains committed to disciplined spending and investments in AI-driven automation and the Ignite interoperability platform.
Why Health Catalyst (HCAT) Shares Are Trading Lower Today
Health Catalyst (HCAT) shares fell 23.1% after the company issued a weak third-quarter revenue forecast and lowered its full-year outlook, despite exceeding second-quarter revenue expectations. The reduced guidance overshadowed the company's Q2 performance and indicates significant challenges ahead. This significant drop follows a recent gain attributed to easing geopolitical tensions and AI-driven M&A in the software sector.
Health Catalyst Shares Tumble Overnight: What Investors Need to Know
Health Catalyst (HCAT) shares plummeted 24.68% in overnight trading after the company issued lower-than-expected third-quarter revenue guidance, despite exceeding its second-quarter revenue guidance. The healthcare intelligence company reported a 13% year-over-year revenue decline in Q2 but saw adjusted EBITDA increase. Investors reacted negatively to the forward-looking financial outlook.
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
Health Catalyst (HCAT) reported Q2 2026 revenue of $70.49 million, exceeding the Zacks Consensus Estimate by 2.33%, despite a 12.7% year-over-year decline. The company's EPS of $0.04 surpassed the consensus estimate of $0.02 by 100%. Key metrics like professional services revenue and adjusted gross profits also largely outperformed analyst expectations.
Health Catalyst (Nasdaq: HCAT) sells Vitalware, ends credit facility debt
Health Catalyst (HCAT) has completed the sale of its Vitalware business to Med-Metrix for $147 million, using the proceeds to fully repay its credit facility debt of $159.9 million. This move is expected to eliminate approximately $19 million in annual interest expenses and will allow Health Catalyst to focus on its core healthcare intelligence strategy. The company reported Q2 2026 revenue of $70.5 million, a 13% year-over-year decrease, and a net loss of $40.5 million, which included a $27.0 million goodwill impairment.
Health Catalyst (NASDAQ: HCAT) books $151.6M loss and $147M Vitalware sale
Health Catalyst, Inc. (NASDAQ: HCAT) reported a net loss of $151.6 million for the first half of 2026, primarily due to a $122.5 million goodwill impairment charge. The company also announced the sale of its Vitalware business to Med-Metrix for $147 million, with the proceeds used to repay outstanding debt. Revenue declined year-over-year, impacting profitability, though operating cash flow improved.
Health Catalyst, Inc. 2026: Revenue $70.49M, EPS ($0.55) — 10-Q Summary
Health Catalyst, Inc. (HCAT) reported Q3 2026 revenue of $70.49 million, a decline from $80.72 million in the prior year, and a net loss of ($0.55) per diluted share. The company attributes the revenue drop to customer churn from DOS-to-Ignite migrations and the exit of lower-margin arrangements. HCAT is implementing "Project Nexus" to improve operational efficiency and anticipates migration-related churn to conclude by the end of 2027.
Press Release: Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Health Catalyst has announced the completion of the sale of its Vitalware business to RLDatix. This strategic move allows Health Catalyst to sharpen its focus on its core healthcare intelligence and analytics offerings, streamlining its operations and strengthening its balance sheet. The company anticipates using the proceeds from the sale for general corporate purposes, including potential investments in growth initiatives and debt reduction.
Earnings call transcript: Health Catalyst posts Q2 2026 revenue beat, shares sink
Health Catalyst (HCAT) reported Q2 2026 revenue above Wall Street expectations, reaching $70.5 million, and adjusted EBITDA at the high end of guidance. However, the company's shares sank by over 27% in after-hours trading due to a weaker full-year outlook, which was primarily impacted by the divestiture of Vitalware and ongoing platform migration costs. Management emphasized a strategic shift towards core technology opportunities, debt elimination, and a multi-year transformation, prioritizing long-term value over short-term results.
M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix
Health Catalyst, a healthcare intelligence company, has completed the sale of its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million. This divestiture allows Health Catalyst to repay its credit facility, eliminating approximately $19 million in annual interest expense, and focus its capital and operational efforts on scaling its core healthcare intelligence platform and AI-driven decisioning tools. The company aims to leverage its 18 years of proprietary analytics and $2.8 billion in documented clinical and financial outcomes to drive sustainable operational change for health systems.
HEALTH CATALYST ($HCAT) Releases Q2 2026 Earnings
HEALTH CATALYST ($HCAT) announced its Q2 2026 earnings, reporting $0.04 per share, beating estimates by $0.01, and revenue of $70.49 million, surpassing estimates. Despite strong earnings, the stock price decreased by 27.83% since market close. The article also details recent hedge fund activity in HCAT stock and analyst price targets.
Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Health Catalyst announced the completion of the sale of its Vitalware business to Med-Metrix, LLC, on July 31, 2026, for $147 million. The company used the proceeds to repay its credit facility debt, eliminating approximately $19 million in annual interest expense. This divestiture allows Health Catalyst to sharpen its focus on its core healthcare intelligence strategy, leveraging its 18 years of proprietary data and AI-driven products to help health systems improve performance across cost, clinical quality, and consumer loyalty.
Health Catalyst Reports Second Quarter 2026 Results
Health Catalyst (Nasdaq: HCAT) reported its financial results for the second quarter ended June 30, 2026, exceeding revenue guidance and adjusting EBITDA. The company's CEO, Ben Albert, highlighted the Vitalware divestiture and debt repayment as significant balance sheet improvements. Health Catalyst also provided its financial outlook for the third quarter and full year 2026, expecting total revenue of $55 million to $56 million for Q3 and $246 million to $249 million for the full year.
Health Catalyst Tries To Reset With A Vitalware Sale
Health Catalyst (HCAT) plans to sell its Vitalware product line for $147 million to reduce debt and improve margins, aiming to refocus on its higher-growth Ignite platform and AI-enabled solutions. While the company faces significant operating losses and negative returns on invested capital, the divestiture could lead to balance sheet repair and a potential re-rating, offering an opportunistic entry for risk-tolerant investors. However, successful execution of its new strategy and the closure of the Vitalware deal are critical for sustained improvement.
Health Catalyst (NASDAQ:HCAT) Exceeds Q2 CY2026 Expectations But Stock Drops 25.5%
Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 results that surpassed revenue expectations but showed a 12.7% year-on-year sales decline. Despite exceeding revenue and adjusted EBITDA estimates, the company's stock dropped 25.5% due to lower-than-expected revenue guidance for the next quarter and the full year, along with decreased full-year EBITDA guidance and negative free cash flow. The report also highlighted weak long-term revenue growth and customer acquisition inefficiencies, leading to a "weaker quarter" overall.
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For
Health Catalyst (HCAT) is scheduled to report its Q2 earnings this Thursday, with analysts expecting a 14.6% year-on-year revenue decline. Last quarter, the company missed revenue guidance, and its stock has remained unchanged over the past month while the data and analytics software segment saw a 9.6% increase. Investors will be looking for insights into the company's performance given the broader sector's positive sentiment.
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For
Health Catalyst (HCAT) is set to report its Q2 earnings, with analysts expecting a 14.6% year-on-year revenue decline. The company beat revenue expectations last quarter but issued slower guidance. While the data and analytics software segment has shown positive investor sentiment, Health Catalyst's stock price has remained unchanged in the last month.
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For
Health Catalyst (HCAT) is set to report its Q2 earnings this Thursday. Analysts expect a 14.6% year-on-year revenue decline, following a Q1 where revenue guidance missed expectations. Despite a slower last quarter, the company has a history of exceeding Wall Street's expectations.
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For
Health Catalyst (HCAT) is set to report its Q2 earnings this Thursday, with analysts expecting a 14.6% year-on-year revenue decline. Despite a slower previous quarter where revenue guidance missed expectations, analysts have reaffirmed their estimates, suggesting stability. The company has a history of surpassing Wall Street expectations, and its stock price has remained unchanged over the last month, heading into earnings with an average analyst price target slightly above its current share price.
Health Catalyst, Inc. expected to post earnings of 3 cents a share - Earnings Preview
Health Catalyst, Inc. (HCAT) is projected to report earnings of 3 cents per share. This earnings preview, sourced from Refinitiv via Reuters, indicates the anticipated financial performance for the company. The full article provides further details on these expectations.
nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks Shares Are Soaring, What You Need To Know
Shares of nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks surged following easing geopolitical tensions and a new wave of AI-driven M&A activity. A diplomatic resolution regarding the Strait of Hormuz led to a drop in Treasury yields, benefiting growth-oriented tech equities. The article also highlights recent strategic dealmaking in the AI sector and provides specific performance details for each company mentioned.
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call to discuss these results at 5:00 pm ET on the same day. Details for accessing the conference call and live audio webcast are provided in the announcement.
Health Catalyst Q2 Results: Operating results due August 6, 2026 after market close
Health Catalyst, Inc. announced it will release its second-quarter 2026 operating results on Thursday, August 6, 2026, after market close. A conference call is scheduled for 5:00 pm ET the same day, with details provided for U.S. and international dial-in, as well as a live audio webcast. The company, a healthcare intelligence firm backed by $2.8 billion in documented outcomes, will also make a replay of the call available for about 90 days.
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on ...
Health Catalyst, Inc. (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. The healthcare intelligence company will host a conference call at 5:00 pm ET on the same day to review the results. Call details and a live audio webcast link are provided for interested parties.
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its second quarter 2026 operating results after market close on Thursday, August 6, 2026. The company will also host a conference call on the same day at 5:00 pm ET to discuss the results. Conference call details and webcast access are provided for interested participants.
Health Catalyst's Aug. 6 call offers a live online webcast
Health Catalyst (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call on the same day at 5:00 p.m. ET to discuss the results, which will be accessible via live audio webcast and available for replay for 90 days. The announcement includes call details and investor relations contacts.
BlackRock (NYSE: BLK) holds 1.5% beneficial stake in Health Catalyst (HCAT)
BlackRock, Inc. has filed an amended Schedule 13G detailing its beneficial ownership in Health Catalyst, Inc. The filing indicates BlackRock holds 1,128,517 shares, representing a 1.5% stake with sole voting and dispositive power. No single underlying client holds more than five percent of Health Catalyst's outstanding common shares.
HCAT|Health Catalyst Inc|Price:2.150|Chg%:+0.070
TradingKey provides a comprehensive stock analysis for Health Catalyst Inc (HCAT), highlighting its stable fundamentals, significant growth potential, and current valuation as fairly valued within the Software & IT Services industry. The report notes high institutional ownership and a "Hold" rating from multiple analysts with a target price of $2.25. Despite good market performance, technical indicators suggest sideways trading between support and resistance levels, making it suitable for range-bound swing trading.
Health Catalyst Inc (HCAT) Institutional Confidence
Health Catalyst Inc (HCAT) has an institutional shareholding score of 7.00, placing it 139th out of 486 in the Software & IT Services industry. The institutional shareholding proportion increased by 3.83% quarter-over-quarter to 84.30%. James Simons is the largest institutional shareholder, holding 0.29% of outstanding shares.
Health Catalyst, Inc. Revenue Breakdown – LSX:A2PH3J
Health Catalyst, Inc. generated a total revenue of €264.91 million last year, with its Technology segment contributing the most at €177.33 million. The United States was the largest regional contributor, accounting for €255.11 million of the company's revenue. These figures provide insight into the primary revenue drivers and geographical focus of Health Catalyst, Inc.
HCAT|Health Catalyst Inc|Price:2.025|Chg%:+0.015
This article provides a detailed financial summary of Health Catalyst Inc (HCAT), presenting its latest earnings, revenue, EPS, and analyst ratings. It breaks down quarterly and annual financial statements, including income statements, balance sheets, and cash flow statements, to offer an in-depth look at the company's financial health. The report covers various financial indicators, historical data, and answers frequently asked questions regarding the company's performance.
HCAT|Health Catalyst Inc|Price:2.025|Chg%:+0.015
Health Catalyst Inc. (HCAT) is a provider of data and analytics technology and services to healthcare organizations, operating through Technology and Professional Services segments. The company's stock closed at $2.070, up 2.99%, with a market cap of $149.10 million. In Q1 2026, its recurring technology business generated the highest revenue, and as of Q1 2026, institutional shareholding increased, with 383 institutions holding shares worth approximately $62.03 million.
Health Catalyst Inc (HCAT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Health Catalyst Inc (HCAT), noting its current valuation score of 8.01, which ranks 296 out of 485 in the Software & IT Services industry. It highlights the company's P/E ratio of -0.56, indicating it is -43.75% below its recent high and -1099.16% above its recent low. Key valuation metrics like P/B, P/S, and P/CF are not disclosed by the company yet.
Impax Asset Management Group (HCAT) discloses 4M-share position in Health Catalyst
Impax Asset Management Group plc has disclosed a beneficial ownership of 4,000,000 shares of Health Catalyst, Inc. common stock, representing 5.41% of the class. This filing indicates that Impax Asset Management LLC, a wholly-owned subsidiary, retains sole voting and dispositive power over these shares. The disclosure is made via a Schedule 13G filing, signaling a passive investment.
Health Catalyst (HCAT) awards 80,691 restricted stock units to company director
Health Catalyst, Inc. (HCAT) director Jill Hoggard Green was awarded 80,691 restricted stock units (RSUs) as compensation, which will vest on the earlier of one year from the grant date or the next Annual Meeting of Stockholders. This grant increases her beneficial ownership to 144,628 shares of common stock. The RSUs were granted under the company's 2019 Stock Option and Incentive Plan and were reported in a recent Form 4 SEC filing.
Health Catalyst shareholders rejected charter restatement to phase out classified board structure
Health Catalyst shareholders recently held their annual meeting where they ratified Ernst & Young as their independent public accounting firm and approved an advisory vote on executive pay. However, a proposed charter restatement aimed at phasing out the classified board structure was not approved. This news brief was generated by AI based on content published by Health Catalyst Inc. via EDGAR.
Health Catalyst, Commerce, and Paycom Shares Plummet, What You Need To Know
Shares of Health Catalyst (NASDAQ:HCAT), Commerce (NASDAQ:CMRC), and Paycom (NYSE:PAYC) experienced significant drops due to weakening market sentiment, primarily driven by deteriorating macro conditions and an unwinding of retail leverage affecting tech stocks. An oil shock, pushing Brent crude past $85 a barrel, is expected to keep Federal Reserve rates higher, increasing the cost of capital and scrutiny on AI investments in the software sector. Despite the downturn, some investors are rotating into oversold enterprise software names as AI trade shifts from infrastructure to application layers, although risks remain for second-tier software companies without clear AI monetization strategies.
Health Catalyst (NASDAQ: HCAT) holders back pay, auditor and retain classified board
Health Catalyst, Inc. (HCAT) stockholders gathered for their annual meeting on July 16, 2026, where they voted on several key proposals. Investors approved executive compensation and ratified Ernst & Young LLP as the independent auditor for the fiscal year 2026, while also electing Class I directors Justin Spencer and Mathew Arens. Notably, a proposal to phase out the company's classified board structure was not approved, indicating a desire to maintain the current governance model.
Health Catalyst, Commerce, and Paycom Shares Plummet, What You Need To Know
Shares of Health Catalyst, Commerce, and Paycom fell due to weakening sentiment driven by deteriorating macro conditions and an unwinding of retail leverage, particularly in tech stocks. A sudden oil shock, pushing Brent crude past $85, is raising expectations for sustained higher interest rates by the Federal Reserve, which could lead to stricter scrutiny of AI investments in the software sector. This market reaction creates potential buying opportunities for high-quality stocks despite the current downturn.
